Abstract: A multistage colored polymer particle is provided, having a core comprising polymerized units of a monoethylenically unsaturated carboxylic acid core monomer and a non-ionic ethylenically unsaturated core monomer; an inner shell comprising polymerized units of a non-ionic ethylenically unsaturated inner shell monomer; a monoethylenically unsaturated carboxylic acid inner shell monomer; optionally, an aliphatic inner shell monomer; and, optionally, a first polymerizable dye monomer; an outer shell comprising polymerized units of a non-ionic ethylenically unsaturated outer shell monomer; a monoethylenically unsaturated non-carboxylic acid outer shell monomer; optionally, a second polymerizable dye monomer; and, optionally, an aliphatic outer shell monomer; wherein the core, when dry, contains at least one void; and wherein the multistage colored polymer particle comprises polymerized units of polymerizable dye monomer.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: A nanoparticle includes a core. The core includes a bio-resorbable polyester and a hydrophilic polymer. The hydrophilic polymer is a portion of the bio-resorbable polyester or a separate polymer. An acylated human lactoferrin-derived peptide is coated onto the core. The acylated human lactoferrin-derived peptide is a peptide with the amino acid sequence SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR or an amino acid sequence, which does not differ by more than 8 amino acid positions from the sequence SEQ ID NO: 1. The N-terminus of the human lactoferrin-derived peptide is acylated with a C16-monoacyl group.

Abstract: The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: A toothpaste product that is laced with, or infused with, a sedative such as the active ingredients in cannabis. The act of brushing one's teeth using the present invention transfers the sedative into the bloodstream through contact with the gums, leading to a more restful sleep.

Abstract: The present invention provides nanoparticle dispersion for topical delivery to skin of a mammal. The nanoparticle dispersion includes: a sorbitan ester surfactant; one or more poly(ethoxylate) surfactants, one or more lipids; and ibuprofen. Methods of preparing various water continuous dispersion of nanoparticles are also provided.

Abstract: The present invention relates to a system for administering a poorly-soluble compound to the skin, the system being capable of exerting an excellent effect by stably impregnating the poorly-soluble compound and effectively delivering the poorly-soluble compound into the skin, and the present invention is technically characterized by a microneedle to which microparticles comprising a poorly-soluble compound are added. In addition, the present invention provides a method for administering a poorly-soluble compound to the skin, the method being characterized by using the microneedle.

Abstract: Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.

Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

Abstract: Compositions and methods are disclosed herein to deliver and anchor nanoscale drug carriers into the extracellular matrix (ECM) of tissues, such as degenerating cartilage or tumor margins, and to provide local and sustained release of drugs.

Abstract: The present invention relates to a drug delivery system having a double core-shell structure and, specifically, to a double nano-drug delivery system having an inner core-shell containing a poorly soluble camptothecin compound and a water-soluble camptothecin compound inside and an amphiphilic polymer shell, and to a manufacturing method therefor. The double core-shell structured particles manufactured by the present invention form very stable particles and show a mono-distribution of particles before and after freeze-drying. The particles of the present invention show excellent results compared with existing monolayer micelles in animal efficacy tests and pharmacokinetic tests, and do not use a surfactant causing hypersensitivity, and thus the use of the particles of the present invention can provide a pharmaceutical composition or a drug delivery system platform, which are safe for the human body.

Abstract: A coating agent for preventing the adsorption of extracellular vesicles represented by exosomes to a tool has been developed. Adsorption of extracellular vesicles to a tool can be prevented by using a coating agent which contains a hydrophilic polymer having a weight average molecular weight of 10,000 or more and 1,000,000 or less, wherein a coated layer formed by the coating agent has a contact angle of 0 degree or more and 30 degrees or less.

Abstract: Compositions comprising a corticosteroid and a beta-adrenergic are useful for treating inflammatory or obstructive airways diseases.

Abstract: A method of manufacturing a therapeutic agent for the treatment of infections includes the steps of preparing a homogeneous solution of poly(DL-lactide-co-glycolide acid), preparing a solution of a peroxygen donor, preparing a solution of an acetyl donor, adding each of the solutions to a quantity of the poly(DL-lactide-co-glycolide acid) solution to produce a resultant mixture, preparing encapsulated nano- or micro-scale particles from the resultant mixture using a microencapsulator, collecting the nano- or micro-scale particles, and subsequently subjecting the particles to a lyophilization process.

Abstract: The present invention relates to a bioactive or real-time and pathogen killing material comprised of a carbon nanostructure (preferably a fullerene but including other functionalized carbon-based nanostructures) that possess potent broad-spectrum antimicrobial properties. The present invention relates to the utilization of functionalized carbon nanostructures as a bioactive antimicrobial substance that is incorporated into a material, including a textile, fabric, solution, salve, or cream. The preferred embodiment of the present invention is fullerene derivatives that are chemically functionalized on the cage with a halogen element. The present invention pertains to a material that is suitable for barrier garments, accessory garments (shoe covers, masks, facial visors, etc.), textiles (bed sheets, blankets, towels, personal clothing, gowns, surgical drapes, curtains, drapes, pads, etc.), filtration matrices (for use in hemodialysis, hemofiltration, etc.

Abstract: The present invention relates to a construct including a porous core, a cargo, and a spacer disposed between the core and the cargo. In some examples, the construct further includes an outer layer composed of a lipid, a polymer, or a combination thereof. Methods of making and employing such constructs are also described herein.

Abstract: Aqueous dispersion containing a hydrophilic metal oxide powder comprising a metal oxide and a surface modification of the metal oxide, wherein a) the metal oxide is selected from the group consisting of TiO2, ZrO2, SiO2, Al2O3, Fe2O3, Fe3O4, Sb2O3, WO3, CeO2 and mixed oxides thereof and b) the surface modification b1) comprises silicon atoms and aluminum atoms and b2) the silicon atoms are at least partly bonded to a hydrocarbon radical via a C atom and b3) the Al/Si molar ratio of the surface modification is 1:2-1:20.

Abstract: A dental treatment material includes: a liquid dispersion of a glass powder; and an inorganic phosphoric acid aqueous solution, wherein the glass powder contains zinc, silicon, and fluorine and does not substantially contain aluminum.

Abstract: Compositions which comprise a gold nanoparticle, dithiolated diethylenetriamine pentaacetic acid (DTDTPA), and a thioctic acid terminated peptide, wherein the DTDTPA is directly linked to the gold nanoparticle surface via an Au—S bond, and wherein the thioctic acid terminated peptide is directly linked to the gold nanoparticle surface via an Au—S bond.